Evidence map›Paper›PMID 38756774›Full record

ReviewFrontiers in immunology2024

Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application.

Rui Zheng, Xiaobin Liu, Yufu Zhang, Yongxian Liu, Yaping Wang, Shutong Guo, Xiaoyan Jin, Jing Zhang, Yuehong Guan, Yusi Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Article
  3. Intratumoral Microbiome of Metastatic Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2026
    Article
  4. Article
  5. Controlled delivery of STING agonist and manganese ion in injectable PLGA implants for enhanced cancer immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rui Zheng *Department of Medical Immunology, Medical College of Yan'an University, Yanan, Shaanxi, China.
Xiaobin Liu *Department of Medical Immunology, Medical College of Yan'an University, Yanan, Shaanxi, China.
Yufu Zhang *Department of Hepatobiliary Surgery, The Affiliated Hospital of Yan'an University, Yan'an, Shaanxi, China.
Yongxian LiuDepartment of Medical Immunology, Medical College of Yan'an University, Yanan, Shaanxi, China.
Yaping WangDepartment of Medical Immunology, Medical College of Yan'an University, Yanan, Shaanxi, China.
Shutong GuoDepartment of Medical Immunology, Medical College of Yan'an University, Yanan, Shaanxi, China.
Xiaoyan JinDepartment of Medical Immunology, Medical College of Yan'an University, Yanan, Shaanxi, China.
Jing ZhangDepartment of Medical Immunology, Medical College of Yan'an University, Yanan, Shaanxi, China.
Yuehong GuanDepartment of Medical Immunology, Medical College of Yan'an University, Yanan, Shaanxi, China.
Yusi LiuDepartment of Medical Immunology, Medical College of Yan'an University, Yanan, Shaanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is a highly aggressive malignant tumor, that is becoming increasingly common in recent years. Despite advances in intensive treatment modalities including surgery, radiotherapy, biological therapy, and targeted therapy, the overall survival rate has not significantly improved in patients with pancreatic cancer. This may be attributed to the insidious onset, unknown pathophysiology, and poor prognosis of the disease. It is therefore essential to identify and develop more effective and safer treatments for pancreatic cancer. Tumor immunotherapy is the new and fourth pillar of anti-tumor therapy after surgery, radiotherapy, and chemotherapy. Significant progress has made in the use of immunotherapy for a wide variety of malignant tumors in recent years; a breakthrough has also been made in the treatment of pancreatic cancer. This review describes the advances in immune checkpoint inhibitors, cancer vaccines, adoptive cell therapy, oncolytic virus, and matrix-depletion therapies for the treatment of pancreatic cancer. At the same time, some new potential biomarkers and potential immunotherapy combinations for pancreatic cancer are discussed. The molecular mechanisms of various immunotherapies have also been elucidated, and their clinical applications have been highlighted. The current challenges associated with immunotherapy and proposed strategies that hold promise in overcoming these limitations have also been discussed, with the aim of offering new insights into immunotherapy for pancreatic cancer.

Indexed as

Cancer VaccinesImmunotherapyPancreatic NeoplasmsAnimalsBiomarkers, TumorCombined Modality TherapyHumansImmune Checkpoint InhibitorsOncolytic VirotherapyBiomarkers, TumorCancer VaccinesImmune Checkpoint Inhibitorsadoptive cell therapycancer vaccinesimmune checkpoint inhibitorsimmune therapypancreatic cancer

Identifiers

PMID38756774
PMCPMC11096556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.